Ontario Cervical Cancer Screening Clinical Practice Guidelines

Journal of Obstetrics and Gynaecology Canada

Volumn 29, Issue 4, 2007, Pages 344-353

  Meg McLachlin, C ^a,e   Mai, Verna ^b   Murphy, Joan ^c   Fung Kee Fung, Michael ^d   Chambers, Alexandra ^b   Oliver, Thomas K ^b   Anderson, Patricia ^e   Bertrand, Monique ^e   Boerner, Scott ^e   Bryson, Peter ^e   Chapman, William ^e   Colgan, Terry ^e   Elit, Laurie ^e   Giede, Christopher ^e   Howlett, Robbi ^e   Johnston, Richard ^e   Lebeau, Sue ^e   Lofsky, Stan ^e   Miyazaki, Joanne ^e   Prasaud, Leela ^e   Roth, Nathan ^e   Michael Shier, R ^e   Taman, Sara ^e   Thompson, Frank ^e   Briere, Carmen ^e   Carey, Mark ^e   Covens, Allan ^e   Bello, Dianne Dal ^e   Daya, Dean ^e   Dodge, Jason ^e   Fung, Michael Fung Kee ^e   Fyles, Anthony ^e   Harrington, Wendy ^e   Hirte, Holger ^e   Kwon, Janice ^e   Lukka, Himu ^e   Oliver, Tom ^e   Rosen, Barry ^e   Verma, Shailendra ^e   Yoshida, Sam ^e   more..

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b CANCER CARE ONTARIO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e NONE

Author keywords

Cancer screening; Cervical; Cervical screening; Practice guidelines

Indexed keywords

ARTICLE; CANCER SCREENING; COCHRANE LIBRARY; DATA ANALYSIS; DATA EXTRACTION; EMBASE; HUMAN; INFORMATION RETRIEVAL; MEDLINE; ONTARIO; PRACTICE GUIDELINE; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; CANADA; FEMALE; MASS SCREENING; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MASS SCREENING; ONTARIO; UTERINE CERVICAL NEOPLASMS;

EID: 34548066658     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)32441-0     Document Type: Article

References (45)

1. National Cancer Institute of Canada Canadian cancer statistics, 2004 2004, National Cancer Institute of Canada, Toronto, Canada.
2. Browman G.P., Levine M.N., Mohide E.A., Hayward R.S.A., Pritchard K.I., Gafni A., et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995, 13:502-512.
3. Hartman K.E., Hall S.A., Nanda K., Boggess J.F., Zolnoun D. Screening for cervical cancer: systematic evidence review No. 25. (Prepared by the Research Triangle Institute-University of North Carolina Evidence-based Practice Center under contract No. 290-97-0011) January 2002, Agency for Healthcare Research and Quality (AHRQ), Rockville (MD), Available from, Accessed February 2, 2007. http://www.ahrq.gov/clinic/serfiles.htm.
4. Saslow D., Runowicz C.D., Solomon D., Moscicki A.B., Smith R.A., Eyre H.J., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002, 52:342-362.
5. American College of Obstetricians and Gynecologists Committee on Practice Bulletins ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol 2003, 102:417-427.
6. Members of the Working Party on Cervical Screening Recommendations for cervical screening 1997. NZ Med J 1998, 111:94-98.
7. Wright T.C., Cox J.T., Massad L.S., Twiggs L.B., Wilkinson E.J. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002, 287:2120-2129.
8. Morrison B.J. Screening for cervical cancer. Canadian Task Force on the Periodic Health Examination 1994, 870-881. Health Canada, Ottawa.
9. Guidelines for the management of asymptomatic women with screen detected abnormalities 2004, National Health and Medical Research Council, Australia.
10. World Health Organization International Agency for Research on Cancer (IARC) IARC confirms efficacy of cervix cancer screening for women 25-65 in reducing mortality. Press Release No.: 151. IARC Cervix Cancer Screening Meeting 2004 Apr 20-27, [cited 2004 May 12], Available from, Accessed January 14, 2007. http://www.iarc.fr/ENG/Press_Releases/archives/pr151a.html.
11. Noorani H.Z., Brown A., Skidmore B., Stuart G.C.E. Liquid-based cytology and human papillomavirus testing in cervical cancer screening. Ottawa: Canadian Coordinating Office for Health Technology Assessment. Technology Report No. 2003, 40.
12. Goblirsch G., Kastner T., Madden J., McGlennen R., Stephenson-Cole J. Liquid-based cervical cytology 2003 Aug, Institute for Clinical Systems Improvement, Bloomington (MN), Technology Assessment Report No.: 76.
13. Payne N., Chilcott J., McGoogan E. Liquid-based cytology in cervical screening: a rapid and systematic review 2000, 4. Health Technology Assessment, Winchester, England.
14. Medical Services Advisory Committee Liquid based cytology for cervical screening August 2002, Medical Services Advisory Committee, Canberra, Australia, 2002. MSAC Reference 12a. Assessment report.
15. McCrory D.C., Matchar D.B., Bastian L., Datta S., Hasselblad V., Hickey J., et al. Evaluation of cervical cytology 1999, 1999. Agency for Health Care Policy and Research (AHCPR), Rockville (MD), Evidence Report/Technology Assessment No.: 5. AHCPR Publication No.: 99-E010.
16. Cuzick J., Sasieni P., Davies P., Adams J., Normand C., Frater A., et al. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999, 3:i-196.
17. Arbyn M., Buntinx F., Van Ranst M., Paraskevaidis E., Martin-Hirsch P., Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004, 96:280-293.
18. Klinkhamer P.J., Meerding W.J., Rosier P.F., Hanselaar A.G. Liquid-based cervical cytology. Cancer 2003, 99:263-271.
19. Cox J.T., Schiffman M., Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003, 188:1406-1412.
20. The ASCUS-LSIL Triage Study (ALTS) Group A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. J Natl Cancer Inst 2003, 188:1393-1400.
21. The ASCUS-LSIL Triage Study (ALTS) Group Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. J Natl Cancer Inst 2003, 188:1383-1392.
22. Quinn M., Babb P., Jones J., Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999, 318:1-5.
23. Patnick J. Cervical cancer screening in England. Eur J Cancer 2000, 36:2205-2208.
24. Bos A.B., van Ballegooijen M., van Oortmarssen G.J., Habbema J.D. Women who participate in spontaneous screening are not at higher risk for cervical cancer than women who attend programme screening. Eur J Cancer 2002, 38:827-831.
25. Nygard J.F., Skare G.B., Thoresen S.O. The cervical cancer-screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 2002, 9:86-91.
26. Adab P., McGhee S.M., Yanova J., Wong C.M., Hedley A.J. Effectiveness and efficiency of opportunistic cervical cancer screening: comparison with organized screening. Med Care 2004, 42:600-609.
27. Peto J., Gilham C., Fletcher O., Matthews F.E. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004, 364:249-256.
28. Colgan T.J., Clarke A., Hakh N., Seidenfeld A. Screening for cervical disease in mature women: strategies for improvement. Cancer 2002, 96:195-203.
29. Bailey J.V., Kavanagh J., Owen C., McLean K.A., Skinner C.J. Lesbians and cervical screening. Br J Gen Pract 2000, 50:481-482.
30. Marrazzo J.M., Koutsky L.A., Kiviat N.B., Kuypers J.M., Stine K. Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am J Pub Health 2001, 91:947-952.
31. Nieminen P., Kallio M., Anttila A., Hakama M. Organised vs. spontaneous Pap-smear screening for cervical cancer: a case-control study. Int J Cancer 1999, 83:55-58.
32. Miller M.G., Sung H.Y., Sawaya G.F., Kearney K.A., Kinney W., Hiatt R.A. Screening interval and risk of invasive squamous cell cervical cancer. Obstet Gynecol 2003, 101:29-37.
33. Sasieni P., Adams J., Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003, 89:88-93.
34. Fethers K., Marks C., Mindel A., Estcourt C.S. Sexually transmitted infections and risk behaviours in women who have sex with women. Sex Transm Infect 2000, 76:345-349.
35. Renshaw A.A., Young N.A., Birdsong G.G., Styer P.E., Davey D.D., Mody D.R., et al. Comparison of performance of conventional and ThinPrep gynecologic preparations in the College of American Pathologists Gynecologic Cytology Program. Arch Pathol Lab Med 2004, 128:17-22.
36. Cheung A.N., Szeto E.F., Leung B.S., Khoo U.S., Ng A.W. Liquid-based cytology and conventional cervical smears: a comparison study in an Asian screening population. Cancer 2003, 99:331-335.
37. Sawaya G.F., McConnell K.J., Kulasingam S.L., Lawson H.W., Kerlikowske K., Melnikow J., et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003, 349:1501-1509.
38. Selvaggi S.M. Reporting of atypical squamous cells, cannot exclude a high-grade squamous intraepithelial lesion (ASC-H) on cervical samples: is it significant?. Diagn Cytopathol 2003, 29:38.
39. Louro A.P., Roberson J., Eltoum I., Chhieng D.C. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion. A follow-up study of conventional and liquid-based preparations in a high-risk population. Am J Clin Pathol 2003, 120:392-397.
40. Hammoud M.M., Haefner H.K., Michael C.W., Ansbacher R. Atypical glandular cells of undetermined significance. Histologic findings and proposed management. J Reprod Med 2002, 47:266-270.
41. Chan C.W., Cheung K.B. Clinical significance and management of cervical atypical glandular cells of undetermined significance. Hong Kong Med J 2003, 9:346-351.
42. Stuart G., Taylor G., Bancej C.M., Beaulac J., Colgan T.J., Franco E.L., et al. Report of the 2003 Pan-Canadian forum on cervical cancer prevention and control. J Obstet Gynaecol Can 2004, 26(11):1004-1028.
43. The AGREE Collaboration. Appraisal of Guidelines Research and Evaluation. AGREE Collaboration 2004 Mar, [Cited 2004 Apr 13], Available from, Accessed September 14, 2007. http://www.agreecollaboration.org/.
44. Cancer Care Ontario [website]. Program in Evidence-Based Care (PEBC). Available at: . Accessed January 30, 2007. http://www.cancercare.on.ca.
45. Gross P.A., Barrett T.L., Dellinger E.P., Krause P.J., Martone W.J., McGowan J.E., et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis 1994, 18:428-430.